Zydus launches Aerolife Mini to simplify inhaler use for asthma and COPD patients

India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease

Glenmark bags FDA nod for generic asthma inhaler with 180-day exclusivity

GSK’s Exdensur wins EU nod for severe asthma

The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen

Trelegy Ellipta gets green light in China for adults with uncontrolled asthma

The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China

GSK’s Exdensur wins Japanese nod for severe asthma

The approval follows robust data from the SWIFT and ANCHOR Phase III trials

Japan nod to Dupixent for children with severe asthma

The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies

GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year

The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease

Fasenra approved in China for the treatment of severe eosinophilic asthma

Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control

AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.